Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
IPO Date: July 24, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $2.48B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.22 | 2.54%
Avg Daily Range (30 D): $0.56 | 1.44%
Avg Daily Range (90 D): $0.78 | 2.12%
Institutional Daily Volume
Avg Daily Volume: .53M
Avg Daily Volume (30 D): .43M
Avg Daily Volume (90 D): .57M
Trade Size
Avg Trade Size (Sh.): 74
Avg Trade Size (Sh.) (30 D): 45
Avg Trade Size (Sh.) (90 D): 50
Institutional Trades
Total Inst.Trades: 5,891
Avg Inst. Trade: $2.34M
Avg Inst. Trade (30 D): $2.52M
Avg Inst. Trade (90 D): $2.38M
Avg Inst. Trade Volume: .05M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $3.2M
Avg Closing Trade (30 D): $4.08M
Avg Closing Trade (90 D): $3.94M
Avg Closing Volume: 77.41K
   
News
Oct 17, 2025 @ 12:00 PM
Agios’ PYRUKYND® (mitapivat) Receives Po...
Source: Agios Pharmaceuticals
Oct 16, 2025 @ 11:00 AM
Agios to Host Third Quarter 2025 Financial Results...
Source: Agios Pharmaceuticals
Sep 22, 2025 @ 5:00 PM
Thalassemia Treatment Market to Witness Significan...
Source: Delveinsight
Sep 15, 2025 @ 11:00 AM
Atavistik Bio Expands Leadership Team with Appoint...
Source: Susan Pandya
Jul 14, 2025 @ 11:00 AM
Agios to Host Webcast Conference Call of Second Qu...
Source: Agios Pharmaceuticals
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $11.45 $-1.93 $-1.55
Diluted EPS $11 $-1.93 $-1.55
Revenue $ 40.88M $ 12.46M $ 8.73M
Gross Profit $ 36.05M $ 10.75M $ 7.64M
Net Income / Loss $ 650.08M $ -112.02M $ -89.29M
Operating Income / Loss $ -461.53M $ -127.06M $ -106.63M
Cost of Revenue $ 4.83M $ 1.7M $ 1.09M
Net Cash Flow $ -3.65M $ 1.91M $ 2.72M
PE Ratio 3.79